Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone-Reference-Cited by-同舟云学术

Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone

Published:2008-11 Issue:16 Volume:44 Page:2506-2517
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Zwolak Pawel,Jasinski Piotr,Terai Kaoru,Gallus Nathan J.,Ericson Marna E.,Clohisy Denis R.,Dudek Arkadiusz Z.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference50 articles.

1. The clinical course of bone metastases from breast cancer;Coleman;Br J Cancer,1987

2. Current management of metastatic breast cancer;Perez;Semin Oncol,1999

3. Predictors of skeletal complications in patients with metastatic breast carcinoma;Domchek;Cancer,2000

4. Strategies for the treatment of cancer pain in the new millennium;Ripamonti;Drugs,2001

5. Prognostic factors in pathologic fractures secondary to metastatic tumors;Narazaki;Clinics,2006

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and validation of an HPLC method for simultaneous determination of imatinib mesylate and rifampicin;Journal of Research in Pharmacy;2022

2. Increased incidence of gastrointestinal toxicity in canine cancer patients treated with concurrent abdominal radiation therapy and toceranib phosphate;Veterinary and Comparative Oncology;2021-08-25

3. Yokukansan Alleviates Cancer Pain by Suppressing Matrix Metalloproteinase-9 in a Mouse Bone Metastasis Model;Evidence-Based Complementary and Alternative Medicine;2019-05-26

4. Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment efficacy;Critical Reviews in Oncology/Hematology;2019-02

5. Radiotherapy and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors in Renal Cancer;Chemotherapy;2018